Evaxion’s AI-Immunology Wins 2026 Prix Galien UK Best Digital Health Award
EVAX•Evaxion’s AI-Immunology™ platform won the 2026 Prix Galien UK Award for Best digital health solution, marking its second Galien recognition within seven months. The award highlights the platform’s AI-driven vaccine target discovery capabilities and enhances Evaxion’s credibility in developing novel cancer and infectious disease vaccines.
1. Prix Galien UK Award Recognition
Evaxion received the 2026 Prix Galien UK Award for Best digital health solution for its AI-Immunology™ platform, selected from ten candidates by a panel of twelve leading scientific experts at the Natural History Museum in London.
2. Platform Innovation and Validation
The award underscores the platform’s ability to decode the human immune system and advance rapid, AI-driven vaccine target discovery and design; this marks Evaxion's second Galien honour, following a Best Medical Technology recognition in December 2025.
3. Strategic Impact and Outlook
External validation of AI-Immunology™ is expected to bolster Evaxion’s credibility in negotiations with partners and investors, potentially accelerating clinical development of its personalized cancer and prophylactic infectious disease vaccine candidates.
